Investor Webinar FDA Approval: A New Chapter for OncoSil CEO & Managing Director, Nigel Lange 17 August 2026 Disclaimer This Presentation has been prepared by OncoSil Medical Ltd (ASX:OSL) ( OncoSil, OSL or the Company ) to provide a general overview of the Company. This Presentation and...
Investor Webinar Presentation
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Earlier from OncoSil Medical
- OncoSil Receives FDA Approval for Distal Cholangiocarcinoma
- Quarterly Activities/Appendix 4C Cash Flow Report
- OncoSil Medical Completes Manufacturing Validation
- OncoSil Medical Files for FDA Approval
- OncoSil Selected for Major European Pancreatic Cancer Study
Later from OncoSil Medical
- Application for quotation of securities - OSL
- Change in substantial shareholding for OSL
- Change in substantial holding
- Appendix 4E and Annual Report
- Appendix 4G and Corporate Governance Statement
Follow OncoSil Medical into a list and get an email when it puts out news.
Follow OncoSil Medical